Latest news

• Bayer drug-device combo for pneumonia flunks phase III test

  However, the study provides important clinical data for this difficult-to-treat disease, ”commented Bayer’s head of development Joerg Moeller.

• Xarelto no better than aspirin in secondary stroke study

  Patients with ESUS currently have limited treatment options and the role of anticoagulants in this area remains uncertain, ”said Joerg Moeller, Bayer's head of development.

• Bayer moves vilaprisan into phase III trials for uterine fibroids

  Dr Joerg Moeller, member of the executive committee of Bayer AG’s pharmaceutical division and head of development, said the work would build on a phase II study of vilaprisan that

• Bayer nets speedy US review for regorafenib in liver cancer

  Dr Joerg Moeller, Bayer's head of development.

• Bayer eyes liver cancer indication for Stivarga

  Effective treatment options are urgently needed for patients with liver cancer,” said Joerg Moeller, Bayer's pharma head, who noted that Stivarga could now sit alongside Nexavar as "the second proven